Pharmena S.A.
Develops patented 1-MNA molecule for dermocosmetics and supplements in EU & North American markets.
PHR | WAR
Overview
Corporate Details
- ISIN(s):
- PLPHRMN00011
- LEI:
- 259400RHT936BBKW0955
- Country:
- Poland
- Address:
- ŁÓDŹ GDAŃSKA 47/49, 90-729 ŁÓDŹ
- Website:
- https://www.pharmena.eu/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Pharmena S.A. is a publicly traded biotechnology and specialty healthcare company focused on the development, manufacturing, and commercialization of innovative products. The company's portfolio is centered around its proprietary and patented active substance, the 1-MNA molecule (marketed as Regen7 molecule®), a naturally occurring niacin metabolite. This molecule is designed to optimize cellular NAD+ levels, which are linked to cellular health and aging. Pharmena's key product lines include dermocosmetics and dietary supplements sold under the Endotelio brand. The company operates in European and North American markets and is also engaged in research and development for new applications of its core technology, including medical devices for wound healing.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Pharmena S.A. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-08 13:56 |
Regulatory News Service
Zawarcie umowy na wykonanie badań biokompatybilności przyszłego wyrobu medyczne…
|
Polish | 1.6 KB | |
| 2025-07-16 10:53 |
Regulatory News Service
Rozpoczęcie współpracy z Shop Apotheke w zakresie sprzedaży suplementów diety w…
|
Polish | 1.2 KB | |
| 2025-07-07 10:12 |
Regulatory News Service
Zawarcie umowy na opracowanie dokumentacji oraz wytworzenie serii walidacyjnych…
|
Polish | 2.0 KB | |
| 2025-06-25 16:52 |
Declaration of Voting Results & Voting Rights Announcements
PHR_Wykaz akcjonariuszy posiad. pow. 5% głosów na ZWZ w dniu 25 06 2025
|
Polish | 50.1 KB | |
| 2025-06-25 16:52 |
Major Shareholding Notification
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ w dniu 25…
|
Polish | 525 bytes | |
| 2025-06-25 16:51 |
Board/Management Information
250625_Informacja dot Jacka Szwajcowskiego
|
Polish | 306.7 KB | |
| 2025-06-25 16:51 |
Board/Management Information
250625_Informacja dot Zbigniewa Molenda
|
Polish | 224.2 KB | |
| 2025-06-25 16:51 |
Board/Management Information
250625_Informacja dot. Anny Paczkowskiej
|
Polish | 239.0 KB | |
| 2025-06-25 16:51 |
Board/Management Information
250625_Informacja dot Tomasz Filipiak
|
Polish | 192.5 KB | |
| 2025-06-25 16:51 |
Board/Management Information
250625_Informacja dot Agnieszki Dziki
|
Polish | 146.7 KB | |
| 2025-06-25 16:51 |
Board/Management Information
250625_Informacja dot Jacka Dauenhauera
|
Polish | 225.0 KB | |
| 2025-06-25 16:51 |
Post-Annual General Meeting Information
Powołanie członków Rady Nadzorczej na nową kadencję - Content (PL)
|
Polish | 1.3 KB | |
| 2025-06-25 16:50 |
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 25 06 2025
|
Polish | 176.8 KB | |
| 2025-06-25 16:50 |
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 25.06.2025 r. - Content (…
|
Polish | 822 bytes | |
| 2025-05-29 14:57 |
Board/Management Information
zal03_Oswiadczenie_Jacek_Szwajcowski.pdf
|
Polish | 646.9 KB |
Automate Your Workflow. Get a real-time feed of all Pharmena S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Pharmena S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
